PART I Overview We are a clinical stage biotherapeutics company focusing on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. We are advancing a portfolio of oral therapeutics using our proprietary delivery technology and we are actively pursuing partnering the technology with third party biopharmaceutical companies for the oral delivery of their biologics...
Q2 FY2026 — expected 2026-08-12
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126417 | EDGAR | 108K words |
| 2025-03-31 | 2024-12-31 | 0000950170-25-047740 | EDGAR | — |
| 2024-03-20 | 2023-12-31 | 0000950170-24-034163 | EDGAR | — |
| 2023-03-22 | 2022-12-31 | 0000950170-23-009178 | EDGAR | — |
| 2022-03-31 | 2021-12-31 | 0000950170-22-005088 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269774 | EDGAR | 27K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105045 | EDGAR | — |
| 2025-05-13 | 2025-03-31 | 0000950170-25-070382 | EDGAR | — |
| 2024-11-14 | 2024-09-30 | 0000950170-24-126763 | EDGAR | — |
| 2024-08-06 | 2024-06-30 | 0000950170-24-091793 | EDGAR | — |
| 2024-05-06 | 2024-03-31 | 0000950170-24-053548 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000950170-23-061137 | EDGAR | — |
| 2023-08-11 | 2023-06-30 | 0000950170-23-041852 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0000950170-23-020554 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024442 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0000950170-22-016492 | EDGAR | — |
| 2022-05-11 | 2022-03-31 | 0000950170-22-009334 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-126240 | EDGAR | 3K words |
| 2026-01-02 | 0001193125-26-001098 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269722 | EDGAR | — |
| 2025-10-27 | 0001193125-25-250614 | EDGAR | — |
| 2025-10-17 | 0001193125-25-241963 | EDGAR | — |
| 2025-08-07 | 0000950170-25-104998 | EDGAR | — |
| 2025-07-16 | 0001193125-25-159793 | EDGAR | — |
| 2025-06-26 | 0000950170-25-090384 | EDGAR | — |
| 2025-05-29 | 0000950170-25-078949 | EDGAR | — |
| 2025-05-20 | 0001193125-25-122872 | EDGAR | — |
96 total filings indexed. 69 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001856725 |
| Ticker | RANI |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | CA |
| Website | https://www.ranitherapeutics.com |
| Listed | 2021-07-30 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report